Claims:

- 1. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 7; (b) an amino acid sequence having at least about 90% identity with the amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 7; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 4 or SEQ ID NO: 6; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of UDP-N-acetylmuramoylalanine-D-glutamate ligase from S. aureus; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 2. (Original) The composition of claim 1, wherein at least about two-thirds of the polypeptide in the sample is soluble.
- 3. (Original) The composition of claim 1, wherein the polypeptide is fused to at least one heterologous polypeptide that increases the solubility or stability of the polypeptide.
- 4. (Original) The composition of claim 1, further comprising a matrix suitable for mass spectrometry.
- 5. (Original) The composition of claim 1, wherein the matrix is a nicotinic acid derivative or a cinnamic acid derivative.
- 6. (Original) A composition of claim 1, wherein the polypeptide is enriched in at least one NMR isotope.
- 7. (Original) The composition of claim 6, wherein the NMR isotope is one of the following: hydrogen-1 (1H), hydrogen-2 (2H), hydrogen-3 (3H), phosphorous-31 (31P), sodium-23 (23Na), nitrogen-14 (14N), nitrogen-15 (15N), carbon-13 (13C) and fluorine-19 (19F).
 - 8. (Original) The composition of claim 6, further comprising a deuterium lock solvent.
- 9. (Original) The composition of claim 8, wherein the deuterium lock solvent is one of the following: acetone (CD3COCD3), chloroform (CDCl3), dichloromethane (CD2Cl2), methylnitrile (CD3CN), benzene (C6D6), water (D2O), diethylether ((CD3CD2)2O), dimethylether ((CD3)2O), N,N-dimethylformamide ((CD3)2NCDO), dimethyl sulfoxide

(CD3SOCD3), ethanol (CD3CD2OD), methanol (CD3OD), tetrahydrofuran (C4D8O), toluene (C6D5CD3), pyridine (C5D5N) and cyclohexane (C6H12).

- 10. (Original) The composition of claim 1, wherein the polypeptide is labeled with a heavy atom.
- 11. (Original) The composition of claim 10, wherein the heavy atom is one of the following: cobalt, selenium, krypton, bromine, strontium, molybdenum, ruthenium, rhodium, palladium, silver, cadmium, tin, iodine, xenon, barium, lanthanum, cerium, praseodymium, neodymium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, tantalum, tungsten, rhenium, osmium, iridium, platinum, gold, mercury, thallium, lead, thorium and uranium.
- 12. (Original) The composition of claim 10, wherein the polypeptide is labeled with seleno-methionine.
- 13. (Original) A crystallized, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 1 or SEQ ID NO: 3; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of UDP-N-acetylmuramoylalanine-D-glutamate ligase from S. aureus, and wherein the polypeptide of (a), (b) or (c) is in crystal form.
- 14. (Original) The crystallized, recombinant polypeptide of claim 13, wherein the polypeptide is labeled with a heavy atom.
- 15. (Original) The crystallized, recombinant polypeptide of claim 13, wherein the polypeptide is labeled with seleno-methionine.
- 16. (Original) The crystallized, recombinant polypeptide of claim 13, which diffracts x-rays to a resolution of about 3.5 Å or better.
- 17. (Original) A crystallized complex comprising the crystallized, recombinant polypeptide of claim 13 and a co-factor, wherein the complex is in crystal form.
- 18. (Original) A crystallized complex comprising the crystallized, recombinant polypeptide of claim 13 and a small organic molecule, wherein the complex is in crystal form.

- 19. (Original) A composition comprising the crystallized, recombinant polypeptide of claim 13 and a cryo-protectant.
- 20. (Original) The composition of claim 19, wherein the cryo-protectant is one of the following: methyl pentanediol, isopropanol, ethylene glycol, glycerol, formate, citrate, mineral oil and a low-molecular-weight polyethylene glycol.
- 21. (Original) A host cell comprising a nucleic acid encoding a polypeptide of claim 1; wherein a culture of the host cell produces at least about 1 of the polypeptide per liter of culture and the polypeptide is at least about one-third soluble as measured by gel electrophoresis.
- 22. (Original) The composition of claim 1, wherein the polypeptide comprises: (a) an amino acid sequence from 1 to at least about 40 amino acids shorter than the amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 7; or (b) an amino acid sequence from 1 to at least about 40 amino acids shorter than an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 7; wherein the polypeptide of (a) or (b) has at least one biological activity of UDP-N-acetylmuramoylalanine-D-glutamate ligase from *S. aureus*; and wherein the polypeptide of (a) or (b) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 23. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 28 or SEQ ID NO: 30; (b) an amino acid sequence having at least about 90% identity with the amino acid sequence set forth in SEQ ID NO: 28 or SEQ ID NO: 30; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 27 or SEQ ID NO: 29; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of UDP-N-acetylmuramate-alanine ligase from S. aureus; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 24. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 47 or SEQ ID NO: 49; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 47 or SEQ ID NO: 49; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a

polynucleotide having SEQ ID NO: 46 or SEQ ID NO: 48; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of UDP-N-acetylenolpyruvylglucosamine reductase from *S. aureus*; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.

- 25. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 56 or SEQ ID NO: 58; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 56 or SEQ ID NO: 58; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 55 or SEQ ID NO: 57; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of mevalonate kinase from *S. aureus*; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 26. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 65 or SEQ ID NO: 67; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 65 or SEQ ID NO: 67; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 64 or SEQ ID NO: 66; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of acetyl-CoA carboxylase carboxyl transferase subunit alpha from *E. coli*; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 27. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 74 or SEQ ID NO: 76; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 74 or SEQ ID NO: 76; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 73 or SEQ ID NO: 75; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of acetyl-CoA carboxylase carboxyl transferase subunit

Response to Restriction Requirement U.S. Application No. 10/806,062 Page 6 of 13

alpha from S. aureus; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.

- 28. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 83 or SEQ ID NO: 85; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 83 or SEQ ID NO: 85; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 82 or SEQ ID NO: 84; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of phosphoglucosamine-mutase from S. aureus; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 29. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 92 or SEQ ID NO: 94; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 92 or SEQ ID NO: 94; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 91 or SEQ ID NO: 93; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of D-alanine-D-alanine ligase A from S. pneumoniae; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 30. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 101 or SEQ ID NO: 103; (b) an amino acid sequence having at least about 90% identity with the amino acid sequence set forth in SEQ ID NO: 101 or SEQ ID NO: 103; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 100 or SEQ ID NO: 102; wherein the polypeptide least biological activity (c) has at one of (a), (b) or phosphoglucomutase/phosphomannomutase family protein from S. pneumoniae; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.

Response to Restriction Requirement U.S. Application No. 10/806,062 Page 7 of 13

- 31. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 120 or SEQ ID NO: 122; (b) an amino acid sequence having at least about 90% identity with the amino acid sequence set forth in SEQ ID NO: 120 or SEQ ID NO: 122; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 119 or SEQ ID NO: 121; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of UDP-N-acetylmuramoylalanine-D-glutamate ligase from S. pneumoniae; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 32. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 140 or SEQ ID NO: 142; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 140 or SEQ ID NO: 142; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 139 or SEQ ID NO: 141; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of methionyl-tRNA synthetase from S. aureus; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 33. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 149 or SEQ ID NO: 151; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 149 or SEQ ID NO: 151; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 148 or SEQ ID NO: 150; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of tyrosyl-tRNA synthetase from S. aureus; and wherein the polypeptide of (a), (b) or (c) is is purified to essential homogeneity.
- 34. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 158 or SEQ ID NO: 160; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 158 or SEQ ID NO: 160; or (c) an amino acid sequence

Response to Restriction Requirement U.S. Application No. 10/806,062 Page 8 of 13

encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 157 or SEQ ID NO: 159; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of histidyl-tRNA synthetase from S. aureus; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.

- 35. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 167 or SEQ ID NO: 169; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 167 or SEQ ID NO: 169; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 166 or SEQ ID NO: 168; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of thymidylate kinase from *S. aureus*; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 36. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 176 or SEQ ID NO: 178; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 176 or SEQ ID NO: 178; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 175 or SEQ ID NO: 177; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of peptide chain release factor RF-1 from S. aureus; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 37. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 185 or SEQ ID NO: 187; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 185 or SEQ ID NO: 187; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 184 or SEQ ID NO: 186; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of histidine tRNA synthetase from S.

Response to Restriction Requirement U.S. Application No. 10/806,062 Page 9 of 13

pneumoniae; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.

- 38. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 194 or SEQ ID NO: 196; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 194 or SEQ ID NO: 196; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 193 or SEQ ID NO: 195; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of BirA bifunctional protein from S. pneumoniae; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 39. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 203 or SEQ ID NO: 205; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 203 or SEQ ID NO: 205; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 202 or SEQ ID NO: 204; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of PTS system enzyme II A component from S. pneumoniae; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 40. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 212 or SEQ ID NO: 214; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 212 or SEQ ID NO: 214; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 211 or SEQ ID NO: 213; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of adenine phosphoribosyltransferase from S. aureus; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.

Response to Restriction Requirement U.S. Application No. 10/806,062 Page 10 of 13

- 41. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 221 or SEQ ID NO: 223; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 221 or SEQ ID NO: 223; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 220 or SEQ ID NO: 222; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of uridylate kinase from S. aureus; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 42. (Original) A composition comprising an isolated, recombinant polypeptide comprising: (a) an amino acid sequence set forth in SEQ ID NO: 230 or SEQ ID NO: 232; (b) an amino acid sequence having at least about 90% identity with the amino acid sequence set forth in SEQ ID NO: 230 or SEQ ID NO: 232; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 229 or SEQ ID NO: 231; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of guanylate kinase from S. pneumoniae; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 43. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 239 or SEQ ID NO: 241; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 239 or SEQ ID NO: 241; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 238 or SEQ ID NO: 240; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of adenine phosphoribosyltransferase from S. pneumoniae; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 44. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 248 or SEQ ID NO: 250; (b) an amino acid sequence having at least about 95% identity with the amino acid

Response to Restriction Requirement U.S. Application No. 10/806,062 Page 11 of 13

sequence set forth in SEQ ID NO: 248 or SEQ ID NO: 250; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 247 or SEQ ID NO: 249; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of uridylate kinase from S. pneumoniae; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.

- 45. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 270 or SEQ ID NO: 272; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 270 or SEQ ID NO: 272; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 269 or SEQ ID NO: 271; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of uridylate kinase from *P. aeruginosa*; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 46. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 279 or SEQ ID NO: 281; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 279 or SEQ ID NO: 281; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 278 or SEQ ID NO: 280; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of phosphoglycerate kinase from S. aureus; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 47. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 288 or SEQ ID NO: 290; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 288 or SEQ ID NO: 290; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 287 or SEQ ID NO: 289; wherein the polypeptide

Response to Restriction Requirement U.S. Application No. 10/806,062 Page 12 of 13

- of (a), (b) or (c) has at least one biological activity of flavoprotein affecting synthesis of DNA and pantothenate from *E. coli*; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 48. (Original) A composition comprising an isolated, recombinant polypeptide comprising: (a) an amino acid sequence set forth in SEQ ID NO: 297 or SEQ ID NO: 299; (b) an amino acid sequence having at least about 90% identity with the amino acid sequence set forth in SEQ ID NO: 297 or SEQ ID NO: 299; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 296 or SEQ ID NO: 298; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of riboflavin kinase/FAD synthase from *S. aureus*; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 49. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 306 or SEQ ID NO: 308; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 306 or SEQ ID NO: 308; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 305 or SEQ ID NO: 307; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of phosphopantetheine adenylyltransferase from *P. aeruginosa*; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.
- 50. (Original) A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 315 or SEQ ID NO: 317; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 315 or SEQ ID NO: 317; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 314 or SEQ ID NO: 316; wherein the polypeptide of (a), (b) or (c) has at least one biological activity of peptide chain release factor 1 from *P. aeruginosa*; and wherein the polypeptide of (a), (b) or (c) is at least about 95% pure as determined by gel electrophoresis in a sample of the composition.